



## Clinical trial results:

**A multicentre, open-label clinical trial to assess plasma levels and safety of bilastine in children from 2 to 5 years of age with seasonal and/or perennial allergic rhinoconjunctivitis or urticaria**

### Summary

EudraCT number	2021-003011-26
Trial protocol	SK LT PL
Global end of trial date	21 April 2022

### Results information

Result version number	v1 (current)
This version publication date	21 March 2024
First version publication date	21 March 2024

### Trial information

#### Trial identification

Sponsor protocol code	BILA-4021/PED
-----------------------	---------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	FAES FARMA, S.A.
Sponsor organisation address	Avenida Autonomía 10, Leioa (Bizkaia) , Spain, 48940
Public contact	Clinical Research Derpartment, FAES FARMA S.A., clinical_rd@faes.es
Scientific contact	Clinical Research Derpartment, FAES FARMA S.A., clinical_rd@faes.es

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	30 June 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	08 April 2022
Global end of trial reached?	Yes
Global end of trial date	21 April 2022
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To obtain bilastine plasma concentrations after the administration of multiple oral doses over a treatment period of 7 (+3) days in children between the ages of 2 and 5 years old with seasonal and/or perennial allergic rhinoconjunctivitis (SAR/PAR) or urticaria.

Protection of trial subjects:

The trial will be conducted in compliance with this protocol, by the trial personnel, who are qualified by education, training, and experienced in their roles, with adherence to Good Clinical Practice (GCP), the applicable regulatory requirements, and ethical principles based on the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 December 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 6
Country: Number of subjects enrolled	Slovakia: 19
Country: Number of subjects enrolled	Lithuania: 14
Worldwide total number of subjects	39
EEA total number of subjects	39

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	39
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0

85 years and over	0
-------------------	---

## Subject disposition

### Recruitment

Recruitment details:

39 subjects were enrolled in 7 active sites in 3 European countries: Lithuania (2 sites), Poland (1 site) and Slovakia (4 sites), 38 subjects were randomised.

### Pre-assignment

Screening details:

Subjects who met all the inclusion criteria and none of the exclusion criteria. 39 subjects were enrolled to the trial. 1 subject was a screening failure, for 1 subject consent was withdrawn before IMP intake.

### Pre-assignment period milestones

Number of subjects started	39
Number of subjects completed	38

### Pre-assignment subject non-completion reasons

Reason: Number of subjects	Screening failures: 1
----------------------------	-----------------------

### Period 1

Period 1 title	Baseline Period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Arm title	Overall - Bilastine
-----------	---------------------

Arm description:

Children aged 2 to 5 years with allergic rhinoconjunctivitis or urticaria. All eligible subjects were treated with a dose of 10 mg bilastine orodispersible tablets once daily and were randomised in a 1:1:1 ratio to one of 3 PK blood sampling groups, stratified by age group ( $\geq 2$  to  $< 4$  years of age;  $\geq 4$  to  $\leq 5$  years of age).

Arm type	Open-label trial with only one treatment arm
Investigational medicinal product name	Bilastine orodispersible tablets 10 mg
Investigational medicinal product code	Bilastine
Other name	Bilaxten
Pharmaceutical forms	Orodispersible tablet
Routes of administration	Oral use

Dosage and administration details:

All subjects received 10 mg of bilastine orally, once daily, preferably in the morning and at the same time every day for 7 (+3) days (all subjects) or 14 (+6) days (based on investigator's decision). The IMP was taken under fasting conditions, 1 hour before or 2 hours after intake of food. In case fruits, fruit juices, meals containing fruits or soft drinks were consumed, the medication was recommended to be taken either 3 hours before or 3 hours afterwards. The details of IMP intake were described in the IMP intake instructions.

Number of subjects in period 1 <sup>[1]</sup>	Overall - Bilastine
Started	38
Completed	37
Not completed	1
Consent withdrawn by subject	1

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Number of subjects in the baseline period are defined as subjects who met all the inclusion criteria and none of the exclusion criteria. 39 subjects were enrolled to the trial. 1 subject was a screening failure

## Period 2

Period 2 title	Overall Treatment Period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

## Arms

Arm title	Overall - Bilastine
-----------	---------------------

Arm description:

Children aged 2 to 5 years with allergic rhinoconjunctivitis or urticaria. All eligible subjects were treated with a dose of 10 mg bilastine orodispersible tablets once daily and were randomised in a 1:1:1 ratio to one of 3 PK blood sampling groups, stratified by age group ( $\geq 2$  to  $< 4$  years of age;  $\geq 4$  to  $\leq 5$  years of age).

Arm type	Open-label trial with only one treatment arm
Investigational medicinal product name	Bilastine orodispersible tablets 10 mg
Investigational medicinal product code	Bilastine
Other name	Bilaxten
Pharmaceutical forms	Orodispersible tablet
Routes of administration	Oral use

Dosage and administration details:

All subjects received 10 mg of bilastine orally, once daily, preferably in the morning and at the same time every day for 7 (+3) days (all subjects) or 14 (+6) days (based on investigator's decision). The IMP was taken under fasting conditions, 1 hour before or 2 hours after intake of food. In case fruits, fruit juices, meals containing fruits or soft drinks were consumed, the medication was recommended to be taken either 3 hours before or 3 hours afterwards. The details of IMP intake were described in the IMP intake instructions.

Number of subjects in period 2	Overall - Bilastine
Started	37
Completed	36
Not completed	1
Consent withdrawn by subject	1

---

**Period 3**

Period 3 title	Completion Period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

**Arms**

<b>Arm title</b>	Overall - Bilastine
------------------	---------------------

Arm description:

Children aged 2 to 5 years with allergic rhinoconjunctivitis or urticaria. All eligible subjects were treated with a dose of 10 mg bilastine orodispersible tablets once daily and were randomised in a 1:1:1 ratio to one of 3 PK blood sampling groups, stratified by age group ( $\geq 2$  to  $< 4$  years of age;  $\geq 4$  to  $\leq 5$  years of age).

Arm type	Open-label trial with only one treatment arm
Investigational medicinal product name	Bilastine orodispersible tablets 10 mg
Investigational medicinal product code	Bilastine
Other name	Bilaxten
Pharmaceutical forms	Orodispersible tablet
Routes of administration	Oral use

Dosage and administration details:

All subjects received 10 mg of bilastine orally, once daily, preferably in the morning and at the same time every day for 7 (+3) days (all subjects) or 14 (+6) days (based on investigator's decision). The IMP was taken under fasting conditions, 1 hour before or 2 hours after intake of food. In case fruits, fruit juices, meals containing fruits or soft drinks were consumed, the medication was recommended to be taken either 3 hours before or 3 hours afterwards. The details of IMP intake were described in the IMP intake instructions.

<b>Number of subjects in period 3</b>	Overall - Bilastine
Started	36
Completed	28
Not completed	8
Agreed with sponsor to skip Visit 4	3
Physician decision	4
Protocol deviation	1

---

**Period 4**

Period 4 title	Follow-Up Period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

## Arms

<b>Arm title</b>	Overall - Bilastine
------------------	---------------------

### Arm description:

Children aged 2 to 5 years with allergic rhinoconjunctivitis or urticaria. All eligible subjects were treated with a dose of 10 mg bilastine orodispersible tablets once daily and were randomised in a 1:1:1 ratio to one of 3 PK blood sampling groups, stratified by age group ( $\geq 2$  to  $< 4$  years of age;  $\geq 4$  to  $\leq 5$  years of age).

Arm type	Open-label trial with only one treatment arm
Investigational medicinal product name	Bilastine orodispersible tablets 10 mg
Investigational medicinal product code	Bilastine
Other name	Bilaxten
Pharmaceutical forms	Orodispersible tablet
Routes of administration	Oral use

### Dosage and administration details:

All subjects received 10 mg of bilastine orally, once daily, preferably in the morning and at the same time every day for 7 (+3) days (all subjects) or 14 (+6) days (based on investigator's decision). The IMP was taken under fasting conditions, 1 hour before or 2 hours after intake of food. In case fruits, fruit juices, meals containing fruits or soft drinks were consumed, the medication was recommended to be taken either 3 hours before or 3 hours afterwards. The details of IMP intake were described in the IMP intake instructions.

<b>Number of subjects in period 4</b>	Overall - Bilastine
Started	28
Completed	28

## Baseline characteristics

### Reporting groups

Reporting group title	Overall - Bilastine
-----------------------	---------------------

Reporting group description:

Children aged 2 to 5 years with allergic rhinoconjunctivitis or urticaria. All eligible subjects were treated with a dose of 10 mg bilastine orodispersible tablets once daily and were randomised in a 1:1:1 ratio to one of 3 PK blood sampling groups, stratified by age group ( $\geq 2$  to  $< 4$  years of age;  $\geq 4$  to  $\leq 5$  years of age).

Reporting group values	Overall - Bilastine	Total	
Number of subjects	38	38	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age $< 37$ wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	38	38	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	0	0	
From 65-84 years	0	0	
85 years and over	0	0	
Age continuous			
Units: years			
arithmetic mean	3.7		
standard deviation	$\pm 1.06$	-	
Gender categorical			
Units: Subjects			
Female	11	11	
Male	27	27	

### Subject analysis sets

Subject analysis set title	Safety population
----------------------------	-------------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

The safety set (SAF) was defined as all subjects who received at least one dose of IMP.

Subject analysis set title	PK-Set
----------------------------	--------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

The PK set was defined as all subjects who received at least one dose of IMP and had at least one plasma concentration result.

Subject analysis set title	PK group 1
----------------------------	------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

Subjects of Safety Set set were randomly assigned to one of the 3 pharmacokinetic (PK) blood sampling groups, the randomisation ratio was 1:1:1 with a stratification by age group (children from  $\geq 2$  to  $< 4$



years of age and children from  $\geq 4$  to  $\leq 5$  years of age).

Subject analysis set title	PK group 2
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Subjects of Safety Set set were randomly assigned to one of the 3 pharmacokinetic (PK) blood sampling groups, the randomisation ratio was 1:1:1 with a stratification by age group (children from  $\geq 2$  to  $< 4$  years of age and children from  $\geq 4$  to  $\leq 5$  years of age).

Subject analysis set title	PK group 3
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Subjects of Safety Set set were randomly assigned to one of the 3 pharmacokinetic (PK) blood sampling groups, the randomisation ratio was 1:1:1 with a stratification by age group (children from  $\geq 2$  to  $< 4$  years of age and children from  $\geq 4$  to  $\leq 5$  years of age).

Reporting group values	Safety population	PK-Set	PK group 1
Number of subjects	37	35	12
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age $< 37$ wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	37	35	12
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous			
Units: years			
arithmetic mean	3.7	3.7	3.6
standard deviation	$\pm 1.06$	$\pm 1.05$	$\pm 1.16$
Gender categorical			
Units: Subjects			
Female	11	11	3
Male	26	24	9

Reporting group values	PK group 2	PK group 3	
Number of subjects	13	12	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age $< 37$ wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	13	12	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	0	0	
From 65-84 years	0	0	
85 years and over	0	0	

Age continuous			
Units: years			
arithmetic mean	3.6	3.8	
standard deviation	± 0.96	± 1.11	
Gender categorical			
Units: Subjects			
Female	3	5	
Male	10	7	

---

## End points

### End points reporting groups

Reporting group title	Overall - Bilastine
Reporting group description: Children aged 2 to 5 years with allergic rhinoconjunctivitis or urticaria. All eligible subjects were treated with a dose of 10 mg bilastine orodispersible tablets once daily and were randomised in a 1:1:1 ratio to one of 3 PK blood sampling groups, stratified by age group ( $\geq 2$ to $< 4$ years of age; $\geq 4$ to $\leq 5$ years of age).	
Reporting group title	Overall - Bilastine
Reporting group description: Children aged 2 to 5 years with allergic rhinoconjunctivitis or urticaria. All eligible subjects were treated with a dose of 10 mg bilastine orodispersible tablets once daily and were randomised in a 1:1:1 ratio to one of 3 PK blood sampling groups, stratified by age group ( $\geq 2$ to $< 4$ years of age; $\geq 4$ to $\leq 5$ years of age).	
Reporting group title	Overall - Bilastine
Reporting group description: Children aged 2 to 5 years with allergic rhinoconjunctivitis or urticaria. All eligible subjects were treated with a dose of 10 mg bilastine orodispersible tablets once daily and were randomised in a 1:1:1 ratio to one of 3 PK blood sampling groups, stratified by age group ( $\geq 2$ to $< 4$ years of age; $\geq 4$ to $\leq 5$ years of age).	
Reporting group title	Overall - Bilastine
Reporting group description: Children aged 2 to 5 years with allergic rhinoconjunctivitis or urticaria. All eligible subjects were treated with a dose of 10 mg bilastine orodispersible tablets once daily and were randomised in a 1:1:1 ratio to one of 3 PK blood sampling groups, stratified by age group ( $\geq 2$ to $< 4$ years of age; $\geq 4$ to $\leq 5$ years of age).	
Subject analysis set title	Safety population
Subject analysis set type	Safety analysis
Subject analysis set description: The safety set (SAF) was defined as all subjects who received at least one dose of IMP.	
Subject analysis set title	PK-Set
Subject analysis set type	Sub-group analysis
Subject analysis set description: The PK set was defined as all subjects who received at least one dose of IMP and had at least one plasma concentration result.	
Subject analysis set title	PK group 1
Subject analysis set type	Sub-group analysis
Subject analysis set description: Subjects of Safety Set set were randomly assigned to one of the 3 pharmacokinetic (PK) blood sampling groups, the randomisation ratio was 1:1:1 with a stratification by age group (children from $\geq 2$ to $< 4$ years of age and children from $\geq 4$ to $\leq 5$ years of age).	
Subject analysis set title	PK group 2
Subject analysis set type	Sub-group analysis
Subject analysis set description: Subjects of Safety Set set were randomly assigned to one of the 3 pharmacokinetic (PK) blood sampling groups, the randomisation ratio was 1:1:1 with a stratification by age group (children from $\geq 2$ to $< 4$ years of age and children from $\geq 4$ to $\leq 5$ years of age).	
Subject analysis set title	PK group 3
Subject analysis set type	Sub-group analysis
Subject analysis set description: Subjects of Safety Set set were randomly assigned to one of the 3 pharmacokinetic (PK) blood sampling groups, the randomisation ratio was 1:1:1 with a stratification by age group (children from $\geq 2$ to $< 4$ years of age and children from $\geq 4$ to $\leq 5$ years of age).	

### Primary: Bilastine plasma concentrations at 0.25 h

End point title	Bilastine plasma concentrations at 0.25 h <sup>[1]</sup>
-----------------	--

End point description:

When comparing the individual subject's data, highest bilastine plasma concentration values were observed 0.5, 1 and 2 hours after IMP intake (up to 583.35 ng/mL, 634.91 ng/mL and 375.81 ng/mL, respectively) while values decreased at 4, 6 and 12 hours after IMP intake to individual values below 100 ng/mL except for one subject with 154.20 ng/mL after 4 hours.  
Here the maximum value (ng/ml) for bilastine plasma concentrations at 0.25 hours after intake is stated.

End point type	Primary
----------------	---------

End point timeframe:

At 0.25h

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary endpoint of this trial was only to assess the values for bilastine plasma concentrations. A PK analysis including PK modelling will be performed out of scope of this trial and results will be provided as a separate report.

End point values	PK-Set			
Subject group type	Subject analysis set			
Number of subjects analysed	35			
Units: ng/mL				
number (not applicable)	219.11			

### Statistical analyses

No statistical analyses for this end point

### Primary: Bilastine plasma concentrations at 0.5 h

End point title	Bilastine plasma concentrations at 0.5 h <sup>[2]</sup>
-----------------	---

End point description:

When comparing the individual subject's data, highest bilastine plasma concentration values were observed 0.5, 1 and 2 hours after IMP intake (up to 583.35 ng/mL, 634.91 ng/mL and 375.81 ng/mL, respectively) while values decreased at 4, 6 and 12 hours after IMP intake to individual values below 100 ng/mL except for one subject with 154.20 ng/mL after 4 hours.  
Here the maximum value (ng/ml) for bilastine plasma concentrations at 0.5 hours after intake is stated.

End point type	Primary
----------------	---------

End point timeframe:

At 0.5 h

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary endpoint of this trial was only to assess the values for bilastine plasma concentrations. A PK analysis including PK modelling will be performed out of scope of this trial and results will be provided as a separate report.

End point values	PK-Set			
Subject group type	Subject analysis set			
Number of subjects analysed	35			
Units: ng/mL				
number (not applicable)	583.35			

## Statistical analyses

No statistical analyses for this end point

### Primary: Bilastine plasma concentrations at 1 h

End point title	Bilastine plasma concentrations at 1 h <sup>[3]</sup>
-----------------	---

End point description:

When comparing the individual subject's data, highest bilastine plasma concentration values were observed 0.5, 1 and 2 hours after IMP intake (up to 583.35 ng/mL, 634.91 ng/mL and 375.81 ng/mL, respectively) while values decreased at 4, 6 and 12 hours after IMP intake to individual values below 100 ng/mL except for one subject with 154.20 ng/mL after 4 hours.

Here the maximum value (ng/ml) for bilastine plasma concentrations at 1 hour after intake is stated.

End point type	Primary
----------------	---------

End point timeframe:

At 1 h.

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary endpoint of this trial was only to assess the values for bilastine plasma concentrations. A PK analysis including PK modelling will be performed out of scope of this trial and results will be provided as a separate report.

End point values	PK-Set			
Subject group type	Subject analysis set			
Number of subjects analysed	35			
Units: ng/mL				
number (not applicable)	634.91			

## Statistical analyses

No statistical analyses for this end point

### Primary: Bilastine plasma concentrations at 2 h

End point title	Bilastine plasma concentrations at 2 h <sup>[4]</sup>
-----------------	---

End point description:

When comparing the individual subject's data, highest bilastine plasma concentration values were observed 0.5, 1 and 2 hours after IMP intake (up to 583.35 ng/mL, 634.91 ng/mL and 375.81 ng/mL, respectively) while values decreased at 4, 6 and 12 hours after IMP intake to individual values below 100 ng/mL except for one subject with 154.20 ng/mL after 4 hours.

Here the maximum value (ng/ml) for bilastine plasma concentrations at 2 hours after intake is stated.

End point type	Primary
----------------	---------

End point timeframe:

At 2 h.

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary endpoint of this trial was only to assess the values for bilastine plasma concentrations. A PK analysis including PK modelling will be performed out of scope of this trial and results will be provided as a separate report.

End point values	PK-Set			
Subject group type	Subject analysis set			
Number of subjects analysed	35			
Units: ng/mL				
number (not applicable)	375.81			

## Statistical analyses

No statistical analyses for this end point

### Primary: Bilastine plasma concentrations at 4 h

End point title	Bilastine plasma concentrations at 4 h <sup>[5]</sup>
-----------------	---

End point description:

When comparing the individual subject's data, highest bilastine plasma concentration values were observed 0.5, 1 and 2 hours after IMP intake (up to 583.35 ng/mL, 634.91 ng/mL and 375.81 ng/mL, respectively) while values decreased at 4, 6 and 12 hours after IMP intake to individual values below 100 ng/mL except for one subject with 154.20 ng/mL after 4 hours.

Here the maximum value (ng/ml) for bilastine plasma concentrations at 4 hours after intake is stated.

End point type	Primary
----------------	---------

End point timeframe:

At 4 h.

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary endpoint of this trial was only to assess the values for bilastine plasma concentrations. A PK analysis including PK modelling will be performed out of scope of this trial and results will be provided as a separate report.

End point values	PK-Set			
Subject group type	Subject analysis set			
Number of subjects analysed	35			
Units: ng/mL				
number (not applicable)	154.20			

## Statistical analyses

No statistical analyses for this end point

### Primary: Bilastine plasma concentrations at 6 h

End point title	Bilastine plasma concentrations at 6 h <sup>[6]</sup>
-----------------	---

End point description:

When comparing the individual subject's data, highest bilastine plasma concentration values were observed 0.5, 1 and 2 hours after IMP intake (up to 583.35 ng/mL, 634.91 ng/mL and 375.81 ng/mL,

respectively) while values decreased at 4, 6 and 12 hours after IMP intake to individual values below 100 ng/mL except for one subject with 154.20 ng/mL after 4 hours.

Here the maximum value (ng/ml) for bilastine plasma concentrations at 6 hours after intake is stated.

End point type	Primary
End point timeframe:	
At 6 h.	

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary endpoint of this trial was only to assess the values for bilastine plasma concentrations. A PK analysis including PK modelling will be performed out of scope of this trial and results will be provided as a separate report.

<b>End point values</b>	PK-Set			
Subject group type	Subject analysis set			
Number of subjects analysed	35			
Units: ng/mL				
number (not applicable)	83.97			

## Statistical analyses

No statistical analyses for this end point

## Primary: Bilastine plasma concentrations at 12 h

End point title	Bilastine plasma concentrations at 12 h <sup>[7]</sup>
End point description:	
When comparing the individual subject's data, highest bilastine plasma concentration values were observed 0.5, 1 and 2 hours after IMP intake (up to 583.35 ng/mL, 634.91 ng/mL and 375.81 ng/mL, respectively) while values decreased at 4, 6 and 12 hours after IMP intake to individual values below 100 ng/mL except for one subject with 154.20 ng/mL after 4 hours.	
Here the maximum value (ng/ml) for bilastine plasma concentrations at 12 hours after intake is stated.	

End point type	Primary
End point timeframe:	
At 12 h.	

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary endpoint of this trial was only to assess the values for bilastine plasma concentrations. A PK analysis including PK modelling will be performed out of scope of this trial and results will be provided as a separate report.

<b>End point values</b>	PK-Set			
Subject group type	Subject analysis set			
Number of subjects analysed	35			
Units: ng/mL				
number (not applicable)	16.74			

## Statistical analyses

No statistical analyses for this end point

### Primary: Bilastine plasma concentrations at 0.25 h

End point title	Bilastine plasma concentrations at 0.25 h <sup>[8]</sup>
-----------------	--

End point description:

When comparing the individual subject's data, highest bilastine plasma concentration values were observed 0.5, 1 and 2 hours after IMP intake (up to 583.35 ng/mL, 634.91 ng/mL and 375.81 ng/mL, respectively) while values decreased at 4, 6 and 12 hours after IMP intake to individual values below 100 ng/mL except for one subject with 154.20 ng/mL after 4 hours.  
Here the minimum value (ng/ml) for bilastine plasma concentrations at 0.25 hours after intake is stated.

End point type	Primary
----------------	---------

End point timeframe:

At 0.25 h.

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary endpoint of this trial was only to assess the values for bilastine plasma concentrations. A PK analysis including PK modelling will be performed out of scope of this trial and results will be provided as a separate report.

End point values	PK-Set			
Subject group type	Subject analysis set			
Number of subjects analysed	35			
Units: ng/mL				
number (not applicable)	0.94			

### Statistical analyses

No statistical analyses for this end point

### Primary: Bilastine plasma concentrations at 0.5 h

End point title	Bilastine plasma concentrations at 0.5 h <sup>[9]</sup>
-----------------	---

End point description:

When comparing the individual subject's data, highest bilastine plasma concentration values were observed 0.5, 1 and 2 hours after IMP intake (up to 583.35 ng/mL, 634.91 ng/mL and 375.81 ng/mL, respectively) while values decreased at 4, 6 and 12 hours after IMP intake to individual values below 100 ng/mL except for one subject with 154.20 ng/mL after 4 hours.  
Here the minimum value (ng/ml) for bilastine plasma concentrations at 0.5 hours after intake is stated.

End point type	Primary
----------------	---------

End point timeframe:

At 0.5 h.

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary endpoint of this trial was only to assess the values for bilastine plasma concentrations. A PK analysis including PK modelling will be performed out of scope of this trial and results will be provided as a separate report.



End point values	PK-Set			
Subject group type	Subject analysis set			
Number of subjects analysed	35			
Units: ng/mL				
number (not applicable)	62.15			

## Statistical analyses

No statistical analyses for this end point

### Primary: Bilastine plasma concentrations at 1 h

End point title	Bilastine plasma concentrations at 1 h <sup>[10]</sup>
-----------------	--

End point description:

When comparing the individual subject's data, highest bilastine plasma concentration values were observed 0.5, 1 and 2 hours after IMP intake (up to 583.35 ng/mL, 634.91 ng/mL and 375.81 ng/mL, respectively) while values decreased at 4, 6 and 12 hours after IMP intake to individual values below 100 ng/mL except for one subject with 154.20 ng/mL after 4 hours.

Here the minimum value (ng/ml) for bilastine plasma concentrations at 1 hour after intake is stated.

End point type	Primary
----------------	---------

End point timeframe:

At 1 h.

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary endpoint of this trial was only to assess the values for bilastine plasma concentrations. A PK analysis including PK modelling will be performed out of scope of this trial and results will be provided as a separate report.

End point values	PK-Set			
Subject group type	Subject analysis set			
Number of subjects analysed	35			
Units: ng/mL				
number (not applicable)	9.12			

## Statistical analyses

No statistical analyses for this end point

### Primary: Bilastine plasma concentrations at 2 h

End point title	Bilastine plasma concentrations at 2 h <sup>[11]</sup>
-----------------	--

End point description:

When comparing the individual subject's data, highest bilastine plasma concentration values were observed 0.5, 1 and 2 hours after IMP intake (up to 583.35 ng/mL, 634.91 ng/mL and 375.81 ng/mL, respectively) while values decreased at 4, 6 and 12 hours after IMP intake to individual values below 100 ng/mL except for one subject with 154.20 ng/mL after 4 hours.

Here the minimum value (ng/ml) for bilastine plasma concentrations at 2 hours after intake is stated.

End point type	Primary
----------------	---------

End point timeframe:

At 2 h.

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary endpoint of this trial was only to assess the values for bilastine plasma concentrations. A PK analysis including PK modelling will be performed out of scope of this trial and results will be provided as a separate report.

End point values	PK-Set			
Subject group type	Subject analysis set			
Number of subjects analysed	35			
Units: ng/mL				
number (not applicable)	70.63			

## Statistical analyses

No statistical analyses for this end point

### Primary: Bilastine plasma concentrations at 4 h

End point title	Bilastine plasma concentrations at 4 h <sup>[12]</sup>
-----------------	--

End point description:

When comparing the individual subject's data, highest bilastine plasma concentration values were observed 0.5, 1 and 2 hours after IMP intake (up to 583.35 ng/mL, 634.91 ng/mL and 375.81 ng/mL, respectively) while values decreased at 4, 6 and 12 hours after IMP intake to individual values below 100 ng/mL except for one subject with 154.20 ng/mL after 4 hours.

Here the minimum value (ng/ml) for bilastine plasma concentrations at 4 hours after intake is stated.

End point type	Primary
----------------	---------

End point timeframe:

At 4 h.

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary endpoint of this trial was only to assess the values for bilastine plasma concentrations. A PK analysis including PK modelling will be performed out of scope of this trial and results will be provided as a separate report.

End point values	PK-Set			
Subject group type	Subject analysis set			
Number of subjects analysed	35			
Units: ng/mL				
number (not applicable)	31.56			

## Statistical analyses

No statistical analyses for this end point

### Primary: Bilastine plasma concentrations at 6 h

End point title	Bilastine plasma concentrations at 6 h <sup>[13]</sup>
-----------------	--

End point description:

When comparing the individual subject's data, highest bilastine plasma concentration values were observed 0.5, 1 and 2 hours after IMP intake (up to 583.35 ng/mL, 634.91 ng/mL and 375.81 ng/mL,

respectively) while values decreased at 4, 6 and 12 hours after IMP intake to individual values below 100 ng/mL except for one subject with 154.20 ng/mL after 4 hours.

Here the minimum value (ng/ml) for bilastine plasma concentrations at 6 hours after intake is stated.

End point type	Primary
----------------	---------

End point timeframe:

At 6 h.

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary endpoint of this trial was only to assess the values for bilastine plasma concentrations. A PK analysis including PK modelling will be performed out of scope of this trial and results will be provided as a separate report.

<b>End point values</b>	PK-Set			
Subject group type	Subject analysis set			
Number of subjects analysed	35			
Units: ng/mL				
number (not applicable)	0.58			

## Statistical analyses

No statistical analyses for this end point

## Primary: Bilastine plasma concentrations at 12 h

End point title	Bilastine plasma concentrations at 12 h <sup>[14]</sup>
-----------------	---

End point description:

When comparing the individual subject's data, highest bilastine plasma concentration values were observed 0.5, 1 and 2 hours after IMP intake (up to 583.35 ng/mL, 634.91 ng/mL and 375.81 ng/mL, respectively) while values decreased at 4, 6 and 12 hours after IMP intake to individual values below 100 ng/mL except for one subject with 154.20 ng/mL after 4 hours.

Here the minimum value (ng/ml) for bilastine plasma concentrations at 12 hours after intake is stated.

End point type	Primary
----------------	---------

End point timeframe:

At 12 h.

Notes:

[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary endpoint of this trial was only to assess the values for bilastine plasma concentrations. A PK analysis including PK modelling will be performed out of scope of this trial and results will be provided as a separate report.

<b>End point values</b>	PK-Set			
Subject group type	Subject analysis set			
Number of subjects analysed	35			
Units: ng/mL				
number (not applicable)	0.20			

## Statistical analyses



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

In this clinical trial all untoward events with onset or worsening after the first intake of IMP until the end of the follow-up period will be defined as TEAEs.

Adverse event reporting additional description:

In this clinical trial all untoward events with onset or worsening after the first intake of IMP until the end of the follow-up period will be defined as TEAEs.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.1
--------------------	------

### Reporting groups

Reporting group title	Overall - Bilastine x Safety Set
-----------------------	----------------------------------

Reporting group description:

Subjects in the Safety Set treated with Bilastine

Serious adverse events	Overall - Bilastine x Safety Set		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 37 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Overall - Bilastine x Safety Set		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 37 (21.62%)		
Injury, poisoning and procedural complications			
PROCEDURAL VOMITING			
subjects affected / exposed	1 / 37 (2.70%)		
occurrences (all)	1		
General disorders and administration site conditions			
FATIGUE			
subjects affected / exposed	1 / 37 (2.70%)		
occurrences (all)	1		
INJECTION SITE HAEMATOMA			

subjects affected / exposed occurrences (all)	1 / 37 (2.70%) 1		
Infections and infestations			
COVID-19			
subjects affected / exposed	1 / 37 (2.70%)		
occurrences (all)	1		
Upper respiratory tract infection			
subjects affected / exposed	1 / 37 (2.70%)		
occurrences (all)	1		
URINARY TRACT INFECTION			
subjects affected / exposed	1 / 37 (2.70%)		
occurrences (all)	1		
VARICELLA			
subjects affected / exposed	1 / 37 (2.70%)		
occurrences (all)	1		
VIRAL INFECTION			
subjects affected / exposed	1 / 37 (2.70%)		
occurrences (all)	1		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported